Experimental intraprostatic injection of bacillus calmette-guerin: A feasibility and safety study

Journal of Urology

Volumn 173, Issue 3, 2005, Pages 996-999

  Kosecka, Urszula ^a   Sowery, Richard D ^a   Morales, Alvaro ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Immunotherapy; Mycobacterium bovis; Prostate; Prostatic neoplasms

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE; CIPROFLOXACIN; METRONIDAZOLE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANUS DISEASE; AUTOPSY; BCG VACCINATION; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DOG; DRUG SAFETY; DYSURIA; FEASIBILITY STUDY; HISTOPATHOLOGY; INFECTION; LYMPHADENOPATHY; MALE; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 13744251077     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000145364.90599.43     Document Type: Conference Paper

References (14)

1. Krejci, K. G., Markiewicz, M. A. and Kwon, E. D.: Immunotherapy for urological malignancies. J Urol, 171: 870, 2004
2. Markiewicz, M. A. and Kast, W. M.: Advances in immunotherapy for prostate cancer. Adv Cancer Res, 87: 159, 2003
3. Fong, L. and Small, E. J.: Immunotherapy for prostate cancer. Semin Oncol, 30: 649, 2003
4. Morales, A., Nickel, J. C., Downey, J., Clark, J. and Van Der Linden, I.: Immunotherapy of an experimental adenocarcinoma of the prostate. J Urol, 153: 1706, 1995
5. Pollard, M. and Luckert, P. H.: The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex on L-W rats. Anticancer Res, 14: 901, 1994
6. Morales, A., Johnston, B., Emerson, L. and Heaton, J. W.: Intralesional administration of biological response modifiers in the treatment of localized cancer of the prostate: a feasibility study. Urology, 50: 495, 1997
7. Hrouda, D., Baban, B., Dunsmuir, W. D., Kirby, R. S. and Dalgleish, A. G.: Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol, 82: 568, 1998
8. Guinan, P., Crispen, R., Baumgartner, G., Rao, R., Totonchi, E., Ablin, R. et al: Adjuvant immunotherapy with bacillus Calmette-Guerin in prostate cancer. Urology, 14: 561, 1979
9. Guinan, P. D., John, T., Baumgartner, G., Sundar, B. and Ablin, R. J.: Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am J Clin Oncol, 5: 65, 1982
10. Merrin, C., Han, T., Klein, E. and Murphy, G. P.: Immunotherapy of prostatic cancer with Bacillus Calmette-Guerin and purified protein derivative. Preliminary results. Urology, 2: 651, 1973
11. Robinson, M. R., Rigby, C., Pugh, R. C. and Dumonde, D. C.: Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate. Br J Urol, 49: 221, 1977
12. Morales, A., Nickel, J. C. and Manley, P. N.: Induction of controlled prostatic tissue necrosis by bacille Calmette-Guerin derivatives. Urol Res, 19: 35, 1991
13. Zbar, B., Bernstein, I. D., Bartlett, G. L., Hanna, M. G., Jr. and Rapp, H. J.: Immunotherapy of cancer: prevention of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst, 49: 119, 1972
14. Kramer, G., Steiner, G. E., Sokol, P., Handisurya, A., Klingler, H. C., Maier, U. et al: Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res, 21: 475, 2001